Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide versus lenalidomide + bortezomib after T cell-depleted non-myeloablative allogeneic stem cell transplantation for relapsed multiple myeloma
NL-OMON26950Phase 2Recruiting
- Sponsor
- HOVON
- Start
- Jul 2011
- Modality
- Small Molecules, Peptides, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lenalidomide, bortezomib, alemtuzumab, melphalan, fludarabine and 1 more in multiple myeloma (MM) (2 arms), sponsored by HOVON. Primary endpoints: Feasibility and toxicity and Failure-free duration at 9 months post allo-SCT. Started Jul 2011; status: recruiting.
02
Drugs
lenalidomidebortezomibalemtuzumabmelphalanfludarabine
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON26950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26950.